Scientists at the NHLBI (National, Heart, Lung, and Blood Institute)—which is a part of the NIH (National Institutes of Health)—have developed a new technique that prevents the obstacle of blood flow, an ordinary fatal problem of TMVR (transcatheter mitral valve replacement). The novel method—called LAMPOON—might surge treatment alternatives for high-risk patients’ earlier disqualified for heart valve surgeries. The study was published in the Journal of the American College of Cardiology. Reportedly, TMVR is utilized to cure mitral valve stenosis, a medical condition in which there is constricting of the valve that hampers blood flow to the main pumping chamber of the heart. It also cures regurgitation, which happens when the valve drips and leads to blood to flow back via the valve.
If untreated, these conditions cause heart enlargement, pulmonary hypertension, blood clots, atrial fibrillation, and heart failure. For frail or elderly patients, TMVR provides a less invasive choose to open heart surgery. At the time of TMVR, doctors restore the mitral valve by carrying an artificial valve with a thin, long, flexible tube known as a catheter, via blood vessels into the heart. But in over 50% of patients, the heart’s structure gets in the way. The heart’s leaflet is shoved back and stops blood flow. This is known as LVOT (left ventricular outflow tract) obstruction, an ordinary and the most fatal complication of TMVR.
On a similar note, recently, a study showed that echocardiograms might assist patients with selection for TMVR. Clinicians should make use of echocardiography—an ultrasound that illustrates the heart’s function and structure—when deciding whether patients experiencing heart failure and a dripping heart valve are possibly to benefit from valve repair, as reported in research. The study was presented at the 68th Annual Scientific Session of American College of Cardiology.